India’s Ranbaxy Applies For New Plant To Make Drugs For U.S.
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories has applied to the U.S. FDA for clearance to build a plant in Punjab to produce drugs for the U.S. market. The plant would be the company's fourth allowed to produce U.S.-bound pharmaceuticals. The other three are being eyed carefully by the same agency for allegedly producing contaminated drugs exported to the United States. Ranbaxy expects U.S. approval for the plant in Mohali by the end of next year. (Click here for more